← Back to Glenmark Pharmaceuticals Ltd. overview
Glenmark Pharmaceuticals Ltd. — 10-Year Financials
Annual P&L, balance sheet, and key ratios from public BSE/NSE filings.
| Period | Revenue | Net Profit | EPS (₹) | Total Assets | Shareholder Equity | ROE (%) | ROCE (%) | D/E | Net Margin (%) |
|---|---|---|---|---|---|---|---|---|---|
| FY2025 | ₹13,146 cr | ₹1,047 cr | ₹37.11 | ₹16,050 cr | ₹8,849 cr | 11.83% | 14.19% | 0.28x | 7.97% |
| FY2024 | ₹11,635 cr | ₹-1,502 cr | ₹-53.22 | ₹14,359 cr | ₹7,848 cr | -19.13% | 6.09% | 0.16x | -12.91% |
| FY2023 | ₹11,432 cr | ₹297 cr | ₹10.53 | ₹19,372 cr | ₹9,474 cr | 3.14% | 4.18% | 0.49x | 2.6% |
| FY2022 | ₹12,174 cr | ₹942 cr | ₹33.37 | ₹17,083 cr | ₹9,087 cr | 10.36% | 13.33% | 0.44x | 7.74% |
Revenue: Total income from operations (₹ crore).
EPS: Earnings per share (₹), basic.
ROE: Net profit / average shareholder equity.
ROCE: EBIT / capital employed.
D/E: Total debt / shareholder equity.
Net Margin: Net profit as a % of revenue.
All figures sourced from public BSE/NSE filings. Ratios are pre-computed estimates and may differ from primary filings due to rounding.
Educational content — not investment adviceAll financial data is sourced from public filings and shown here for educational purposes only. EquitiesIndia.com is not a SEBI-registered Investment Adviser or Research Analyst. Nothing on this page constitutes a recommendation or solicitation to transact in any security. All data is at least 90 days old. Past performance is not indicative of future results.